NCT06385158View on ClinicalTrials.gov

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population

PHASE1CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

January 6, 2024

Study Completion Date

November 5, 2024

Conditions

Vasomotor System; LabileHealthy Volunteer

Interventions

DRUG

GS1-144 tablet

GS1-144 tablet is an NK3R antagonist.

Trial Locations (1)

200040

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY

NCT06385158 - A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population | Biotech Hunter | Biotech Hunter